Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®
Oslo, May 2, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a five-year agreement with Orexigen Therapeutics Ireland, Ltd., the subsidiary of the American biopharmaceutical company Orexigen Therapeutics, Inc. (Nasdaq: OREX), for Nordic marketing and distribution of Mysimba®, a prescription pharmaceutical. "We are very pleased to announce the agreement with Orexigen Therapeutics for distribution of the prescription anti-obesity pharmacutical Mysimba (naltrexone HCl/bupropion HCl prolonged release), in the